Advertisement

Journal of Gastrointestinal Surgery

, Volume 23, Issue 1, pp 122–134 | Cite as

Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms

  • Jeffery Chakedis
  • Eliza W. Beal
  • Alexandra G. Lopez-Aguiar
  • George Poultsides
  • Eleftherios Makris
  • Flavio G. Rocha
  • Zaheer Kanji
  • Sharon Weber
  • Alexander Fisher
  • Ryan Fields
  • Bradley A. Krasnick
  • Kamran Idrees
  • Paula Marincola-Smith
  • Clifford Cho
  • Megan Beems
  • Timothy M. Pawlik
  • Shishir K Maithel
  • Carl R. Schmidt
  • Mary DillhoffEmail author
2018 SSAT Plenary Presentation

Abstract

Introduction

Patients with metastatic neuroendocrine tumor (NET) often have an indolent disease course yet the outcomes for patients with metastatic NET undergoing surgery for non-hormonal (NH) symptoms of GI obstruction, bleeding, or pain is not known.

Methods

We identified patients with metastatic gastroenteropancreatic NET who underwent resection from 2000 to 2016 at 8 academic institutions who participated in the US Neuroendocrine Tumor Study Group.

Results

Of 581 patients with metastatic NET to liver (61.3%), lymph nodes (24.1%), lung (2.1%), and bone (2.5%), 332 (57.1%) presented with NH symptoms of pain (n = 223, 67.4%), GI bleeding (n = 54, 16.3%), GI obstruction (n = 49, 14.8%), and biliary obstruction (n = 22, 6.7%). Most patients were undergoing their first operation (85.4%) within 4 weeks of diagnosis. The median overall survival was 110.4 months, and operative intent predicted survival (p < 0.001) with 66.3% undergoing curative resection. Removal of all metastatic disease was associated with the longest median survival (112.5 months) compared to debulking (89.2 months), or palliative resection (50.0 months; p < 0.001). The 1-, 3-, and 12-month mortality was 3.0%, 4.5%, and 9.0%, respectively. Factors associated with 1-year mortality included palliative operations (OR 6.54, p = 0.006), foregut NET (5.62, p = 0.042), major complication (4.91, p = 0.001), and high tumor grade (11.2, p < 0.001). The conditional survival for patients who lived past 1 year was 119 months.

Conclusions

Patients with metastatic NET and NH symptoms that necessitate surgery have long-term survival, and goals of care should focus on both oncologic and quality of life impact. Surgical intervention remains a critical component of multidisciplinary care of symptomatic patients.

Keywords

Neuroendocrine tumor Metastatic Non-hormonal Symptoms Palliative surgery 

Notes

Authors’ Contributions

Study Design: Jeffery Chakedis, Eliza W. Beal, Timothy M. Pawlik, Carl R. Schmidt, Mary Dillhoff.

Data Acquisition: Jeffery Chakedis, Eliza W. Beal, Alexandra G. Lopez-Aguiar, George Poultsides, Eleftherios Makris, Flavio G. Rocha, Zaheer Kanji, Sharon Weber, Alexander Fisher, Ryan Fields, Bradley A. Krasnick, Kamran Idrees, Paula Marincola-Smith, Clifford Cho, Megan Beems, Timothy M. Pawlik, Shishir K Maithel, Carl R. Schmidt, Mary Dillhoff.

Data Analysis/Interpretation: Jeffery Chakedis, Eliza W. Beal, Carl R. Schmidt, Mary Dillhoff.

Manuscript Preparation/Approval: Jeffery Chakedis, Eliza W. Beal, Alexandra G. Lopez-Aguiar, George Poultsides, Eleftherios Makris, Flavio G. Rocha, Zaheer Kanji, Sharon Weber, Alexander Fisher, Ryan Fields, Bradley A. Krasnick, Kamran Idrees, Paula Marincola-Smith, Clifford Cho, Megan Beems, Timothy M. Pawlik, Shishir K Maithel, Carl R. Schmidt, Mary Dillhoff.

Compliance with Ethical Standards

The institutional review board from each institution approved the study

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

11605_2018_3986_MOESM1_ESM.pdf (97 kb)
Supplemental Figure 1 Conditional overall survival of metastatic neuroendocrine tumor patients with non-hormonal symptoms who survived more than 1-year, n=302. (PDF 97 kb)

References

  1. 1.
    Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8–21.CrossRefGoogle Scholar
  2. 2.
    Pavel M, O'Toole D, Costa F, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172–185.CrossRefGoogle Scholar
  3. 3.
    Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010;39(6):753–766.CrossRefGoogle Scholar
  4. 4.
    Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–4663.CrossRefGoogle Scholar
  5. 5.
    Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233.CrossRefGoogle Scholar
  6. 6.
    Mayo SC, Herman JM, Cosgrove D, et al. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg. 2013;216(1):123–134.CrossRefGoogle Scholar
  7. 7.
    Woltering EA, Voros BA, Beyer DT, et al. Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution. J Am Coll Surg. 2017;224(4):434–447.CrossRefGoogle Scholar
  8. 8.
    Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17(12):3129–3136.CrossRefGoogle Scholar
  9. 9.
    Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–534.CrossRefGoogle Scholar
  10. 10.
    Baptiste GG, Postlewait LM, Ethun CG, et al. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years. J Surg Oncol. 2016;114(2):163–169.CrossRefGoogle Scholar
  11. 11.
    Partelli S, Maurizi A, Tamburrino D, et al. GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors. Eur J Endocrinol. 2014;171(4):R153–162.CrossRefGoogle Scholar
  12. 12.
    Arrese D, McNally ME, Chokshi R, et al. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma. Ann Surg Oncol. 2013;20(4):1114–1120.CrossRefGoogle Scholar
  13. 13.
    Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–196.CrossRefGoogle Scholar
  14. 14.
    Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25(3):458–511.CrossRefGoogle Scholar
  15. 15.
    Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37.Google Scholar
  16. 16.
    Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513.CrossRefGoogle Scholar
  17. 17.
    Pavel ME, Singh S, Strosberg JR, et al. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(10):1411–1422.CrossRefGoogle Scholar
  18. 18.
    Spolverato G, Bagante F, Wagner D, et al. Quality of life after treatment of neuroendocrine liver metastasis. J Surg Res. 2015;198(1):155–164.CrossRefGoogle Scholar
  19. 19.
    Spolverato G, Vitale A, Ejaz A, et al. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. Surgery. 2015;158(2):339–348.CrossRefGoogle Scholar
  20. 20.
    Jimenez-Fonseca P, Carmona-Bayonas A, Martin-Perez E, et al. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2015;34(3):381–400.CrossRefGoogle Scholar
  21. 21.
    Yadegarfar G, Friend L, Jones L, et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013;108(2):301–310.CrossRefGoogle Scholar
  22. 22.
    Gaujoux S, Gonen M, Tang L, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol. 2012;19(13):4270–4277.CrossRefGoogle Scholar
  23. 23.
    Birnbaum DJ, Turrini O, Vigano L, et al. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Ann Surg Oncol. 2015;22(3):1000–1007.CrossRefGoogle Scholar
  24. 24.
    Howe JR, Cardona K, Fraker DL, et al. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46(6):715–731.CrossRefGoogle Scholar
  25. 25.
    Daskalakis K, Karakatsanis A, Stalberg P, Norlen O, Hellman P. Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br J Surg. 2017;104(1):69–75.CrossRefGoogle Scholar
  26. 26.
    Laskaratos FM, Rombouts K, Caplin M, Toumpanakis C, Thirlwell C, Mandair D. Neuroendocrine tumors and fibrosis: An unsolved mystery?. Cancer. 2017;123(24):4770–4790.CrossRefGoogle Scholar
  27. 27.
    Ohrvall U, Eriksson B, Juhlin C, et al. Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg. 2000;24(11):1402–1408.CrossRefGoogle Scholar
  28. 28.
    Kulke MH, Shah MH, Benson AB, 3rd, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015;13(1):78–108.Google Scholar
  29. 29.
    Strosberg JR, Fisher GA, Benson AB, et al. Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World J Gastroenterol. 2015;21(8):2450–2459.CrossRefGoogle Scholar
  30. 30.
    Kim SJ, Kim JW, Han SW, et al. Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer. 2010;10:448.CrossRefGoogle Scholar
  31. 31.
    Deutsch GB, Lee JH, Bilchik AJ. Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine Carcinoma. J Am Coll Surg. 2015;221(1):26–36.CrossRefGoogle Scholar
  32. 32.
    Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009;89(4):471–476.CrossRefGoogle Scholar
  33. 33.
    Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–597.CrossRefGoogle Scholar
  34. 34.
    Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072.CrossRefGoogle Scholar
  35. 35.
    Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794–1803.CrossRefGoogle Scholar
  36. 36.
    Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013;24(12):3040–3044.CrossRefGoogle Scholar
  37. 37.
    Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814–2823.CrossRefGoogle Scholar
  38. 38.
    Ilett EE, Langer SW, Olsen IH, Federspiel B, Kjaer A, Knigge U. Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel). 2015;5(2):119–176.CrossRefGoogle Scholar
  39. 39.
    Brennan SM, Gregory DL, Stillie A, Herschtal A, Mac Manus M, Ball DL. Should extrapulmonary small cell cancer be managed like small cell lung cancer?. Cancer. 2010;116(4):888–895.CrossRefGoogle Scholar
  40. 40.
    Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12(6):427–433.CrossRefGoogle Scholar
  41. 41.
    Artinyan A, Orcutt ST, Anaya DA, Richardson P, Chen GJ, Berger DH. Infectious postoperative complications decrease long-term survival in patients undergoing curative surgery for colorectal cancer: a study of 12,075 patients. Ann Surg. 2015;261(3):497–505.CrossRefGoogle Scholar
  42. 42.
    Scaife CL, Hartz A, Pappas L, et al. Association between postoperative complications and clinical cancer outcomes. Ann Surg Oncol. 2013;20(13):4063–4066.CrossRefGoogle Scholar
  43. 43.
    Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.CrossRefGoogle Scholar
  44. 44.
    Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008;144(4):645–651; discussion 651-643.CrossRefGoogle Scholar
  45. 45.
    Gulec SA, Mountcastle TS, Frey D, et al. Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg. 2002;68(8):667–671; discussion 671-662.Google Scholar
  46. 46.
    Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125–135.CrossRefGoogle Scholar
  47. 47.
    Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014;43(4):518–525.CrossRefGoogle Scholar
  48. 48.
    Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol. 2004;22(13):2724–2729.CrossRefGoogle Scholar
  49. 49.
    Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011;52(9):1361–1368.CrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2018

Authors and Affiliations

  • Jeffery Chakedis
    • 1
  • Eliza W. Beal
    • 1
  • Alexandra G. Lopez-Aguiar
    • 2
  • George Poultsides
    • 3
  • Eleftherios Makris
    • 3
  • Flavio G. Rocha
    • 4
  • Zaheer Kanji
    • 4
  • Sharon Weber
    • 5
  • Alexander Fisher
    • 5
  • Ryan Fields
    • 6
  • Bradley A. Krasnick
    • 6
  • Kamran Idrees
    • 7
  • Paula Marincola-Smith
    • 7
  • Clifford Cho
    • 8
  • Megan Beems
    • 8
  • Timothy M. Pawlik
    • 1
  • Shishir K Maithel
    • 2
  • Carl R. Schmidt
    • 1
  • Mary Dillhoff
    • 1
    Email author
  1. 1.Division of Surgical OncologyThe Ohio State University Wexner Medical Center and James Comprehensive Cancer CenterColumbusUSA
  2. 2.Division of Surgical Oncology, Department of Surgery, Emory UniversityWinship Cancer InstituteAtlantaUSA
  3. 3.Department of SurgeryStanford UniversityPalo AltoUSA
  4. 4.Department of SurgeryVirginia Mason Medical CenterSeattleUSA
  5. 5.Department of SurgeryUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  6. 6.Department of SurgeryWashington University School of MedicineSt. LouisUSA
  7. 7.Division of Surgical Oncology, Department of SurgeryVanderbilt UniversityNashvilleUSA
  8. 8.Division of Hepatopancreatobiliary and Advanced Gastrointestinal Surgery, Department of SurgeryUniversity of MichiganAnn ArborUSA

Personalised recommendations